Findings

What do systematic reviews say?

408 questions · 425 findings · 35 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 65 · 15.3%GRADE not reported 37 · 8.7%Very low 86 · 20.2%Low 133 · 31.3%Moderate 88 · 20.7%High 16 · 3.8%

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Total studies: 4 RCTs Total Participants: 3454 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 3454 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 1 RCT; 1223 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1223 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

HD‐TRIPLE (Direct evidence; 0 RCTs; 0 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
Low

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

Total studies: 4 RCTs Total Participants: 4809 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
4 studies · 4809 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 2 RCTs; 2815 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 2815 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 1 RCT; 1071 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1071 participants
Moderate

Intervention not reported

HD‐TRIPLE (Direct evidence; 1 RCT; 1088 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1088 participants
Moderate

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
1
Studies not reported
GRADE not reported

Intervention not reported

Total studies: 7 RCTs Total Participants: 10453 · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
7 studies · 10453 participants
GRADE not reported

Intervention not reported

HD‐ICS/LABA (Direct evidence; 3 RCTs; 3700 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3700 participants
Moderate

Intervention not reported

MD‐TRIPLE (Direct evidence; 3 RCTs; 3063 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 3063 participants
Low

Intervention not reported

HD‐TRIPLE (Direct evidence; 2 RCTs; 1916 participants) · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1916 participants
Low

Intervention not reported

MD‐ICS/LABA · Adolescents and adults with symptomatic asthma Interventions: HD‐ICS/LABA, MD‐TRIPLE, HD‐TRIPLE Comparator (reference): Medium‐Dose…

The review found no eligible studies for this question.

1 finding from 1 review

Effectiveness and tolerability of dual and triple combination inhaler therapies compared with each other and varying… 2022 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Telerehabilitation vs centre‐based (outpatient) pulmonary rehabilitation

Primary rehabilitation · Chronic respiratory disease

The review found no eligible studies for this question.

1 finding from 1 review

Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Telerehabilitation vs centre‐based (outpatient) pulmonary rehabilitation

Exercise capacity · Chronic respiratory disease

Telerehabilitation showed no clear difference in exercise capacity ‐6MWD (m) compared with centre‐based (outpatient) pulmonary rehabilitation (moderate certainty).

1 finding from 1 review

Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
MD 0.06
4 studies · 556 participants
Moderate

Telerehabilitation vs centre‐based (outpatient) pulmonary rehabilitation

Dyspnea · Chronic respiratory disease

Telerehabilitation showed no clear difference in breathlessness ‐ CRQ dyspnoea domain compared with centre‐based (outpatient) pulmonary rehabilitation (low certainty).

1 finding from 1 review

Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
MD 0.13
3 studies · 394 participants
Low

Telerehabilitation vs centre‐based (outpatient) pulmonary rehabilitation

SGRQ Total SGRQ (Total) Score. Scale from: 0 to 100. Lower score indicates better quality of life. · Chronic respiratory disease

Telerehabilitation showed no clear difference in quality of life ‐ SGRQ compared with centre‐based (outpatient) pulmonary rehabilitation (low certainty).

1 finding from 1 review

Telerehabilitation for chronic respiratory disease 2021 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 274 participants
Low